https://orcid.org/0000-0002-0565-6231
-
Views
-
Cite
Cite
J. Borok, P. Gangar, S. Admani, J. Proudfoot, S.F. Friedlander, Safety and efficacy of topical timolol treatment of infantile haemangioma: a prospective trial, British Journal of Dermatology, Volume 178, Issue 1, 1 January 2018, Pages e51–e52, https://doi.org/10.1111/bjd.15865
Close - Share Icon Share
Extract
Funding sources: this was an investigator‐initiated study with support from Valeant Pharmaceuticals. The Clinical and Translational Research Institute is partially supported by the National Institutes of Health (NIH), Grant UL1TR001442 of CTSA funding. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Conflicts of interest: S.F.F. has been on an advisory board for Valeant Pharmaceuticals and received grants and support for investigations into the therapy of haemangiomas.
Dear Editor, Topical timolol therapy is considered a relatively ‘safer’ alternative for the treatment of infantile haemangiomas (IH); however, sufficient supportive pharmacokinetic data does not exist. Most efficacy studies have not evaluated systemic absorption.1,2,3,4,5 To our knowledge, this is the first prospective trial (trial registration: NCT02145884) to assess the clinical response of proliferating IH to topical timolol maleate 0·5% gel‐forming solution and to determine if systemic absorption occurred.
The study was approved by the University of California San Diego institutional review board and 26 infants with IH were enrolled. These infants, aged 5–24 weeks, did not require systemic treatment and received timolol for 4 months. IH ≤ 2 cm in diameter received one drop twice daily; larger lesions received two drops twice daily.
